Skip to main content
Interview with the Innovators
PSMA-Targeted Imaging for Prostate Cancer Treatment
PET/CT Imaging in Prostate Cancer Patients
PSMA-Targeted Imaging for Prostate Cancer Treatment
By Neal Shore, MD, FACS
Interview with the Innovators
Dr Neal Shore discusses the rationale of prostate-specific membrane antigen (PSMA) PET/CT to guide prostate cancer treatment. Learn More ›
Overview of Current Imaging Modalities in Prostate Cancer
PET/CT Imaging in Prostate Cancer Patients
Overview of Current Imaging Modalities in Prostate Cancer
By Neal Shore, MD, FACS
Interview with the Innovators
Dr Neal Shore introduces the current global landscape of various imaging modalities for prostate cancer, including a new prostate-specific membrane antigen (PSMA)-targeted PET/CT agent, PYLARIFY® (piflufolastat F 18). Learn More ›
Making a Difference with Early Identification and Treatment of Patients with NTRK Gene Fusions
NTRK Gene Fusions
Making a Difference with Early Identification and Treatment of Patients with NTRK Gene Fusions
By Ezra Cohen, MD, FRCPSC, FASCO; Mary Jo Fidler, MD; Arturo Loaiza-Bonilla, MD, MSEd, FACP
Interview with the Innovators
Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler of Rush University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, explain the benefits of testing for TRK fusion–positive tumors early for improved clinical outcomes. Learn More ›
Real-World Management of Thyroid Cancer with TRK Inhibitors
NTRK Gene Fusions
Real-World Management of Thyroid Cancer with TRK Inhibitors
By Ezra Cohen, MD, FRCPSC, FASCO; Mary Jo Fidler, MD
Interview with the Innovators
Dr Ezra Cohen of UC San Diego, La Jolla, CA, and Dr Mary Fidler of Rush University Medical Center, Chicago, IL, recount their clinical experiences and the journeys of patients treated with TRK inhibitors for thyroid cancer. Learn More ›
Real-World Experience with TRK Inhibitors in Patients with Lung and Colon Cancers
NTRK Gene Fusions
Real-World Experience with TRK Inhibitors in Patients with Lung and Colon Cancers
By Ezra Cohen, MD, FRCPSC, FASCO; Mary Jo Fidler, MD; Arturo Loaiza-Bonilla, MD, MSEd, FACP
Interview with the Innovators
Dr Mary Fidler of Rush University Medical Center, Chicago, IL, and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, describe their practical experiences with TRK inhibitors in patients with lung cancer and colorectal cancer. Learn More ›
Distinctions and Parallels Among TRK Inhibitors
NTRK Gene Fusions
Distinctions and Parallels Among TRK Inhibitors
By Ezra Cohen, MD, FRCPSC, FASCO; Mary Jo Fidler, MD; Arturo Loaiza-Bonilla, MD, MSEd, FACP
Interview with the Innovators
Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler of Rush University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, explore the mutual and contrasting features of TRK inhibitors. Learn More ›
NTRK Gene Fusion Enrichment in Patient Subpopulations
NTRK Gene Fusions
NTRK Gene Fusion Enrichment in Patient Subpopulations
By Ezra Cohen, MD, FRCPSC, FASCO; Mary Jo Fidler, MD; Arturo Loaiza-Bonilla, MD, MSEd, FACP
Interview with the Innovators
Dr Ezra Cohen of UC San Diego, La Jolla, CA, and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, identify specific subpopulations of patients in which NTRK gene fusions may be commonly uncovered. Learn More ›
Occurrence of TRK Fusion–Positive Tumors in Different Cancer Types
NTRK Gene Fusions
Occurrence of TRK Fusion–Positive Tumors in Different Cancer Types
By Ezra Cohen, MD, FRCPSC, FASCO; Mary Jo Fidler, MD; Arturo Loaiza-Bonilla, MD, MSEd, FACP
Interview with the Innovators
Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler of Rush University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, confer on the categorization of various cancer types in which NTRK gene fusions may be detected. Learn More ›
Significance of Early and Broad Testing of Tumor Mutations
NTRK Gene Fusions
Significance of Early and Broad Testing of Tumor Mutations
By Ezra Cohen, MD, FRCPSC, FASCO; Mary Jo Fidler, MD; Arturo Loaiza-Bonilla, MD, MSEd, FACP
Interview with the Innovators
Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler of Rush University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, discuss how testing for tumor mutations early and broadly may lead to better treatment outcomes. Learn More ›

Page 4 of 6